Literature DB >> 19321994

Reverse cholesterol transport pathway in experimental chronic renal failure.

Hamid Moradi1, Jun Yuan, Zhemin Ni, Keith Norris, Nosratola D Vaziri.   

Abstract

BACKGROUND: Chronic renal failure (CRF) causes oxidative stress, inflammation, oxidation of lipoproteins, impaired maturation of HDL and accelerated atherosclerosis. Uptake of oxidized lipoproteins by macrophages via scavenger receptors (scavenger receptor class A type I--SR-AI, and lectin-like oxidized LDL receptor--LOX-1) leads to foam cell formation and atherosclerosis. HDL mitigates atherosclerosis by retrieving surplus cholesterol via ATP binding cassette transporter A1 (ABCA1) and ABCG1 transporters whose expression is regulated by liver X receptor (LXR). Free cholesterol reaching the surface of HDL is esterified by lecithin-cholesterol acyltransferase (LCAT) and sequestered in the core of HDL, thereby maximizing cholesterol uptake. In the liver, lipid-rich HDL unloads its lipid contents via reversible binding to SR-BI while lipid-poor HDL is degraded by the holo-receptor (ATP synthase beta-chain).
METHODS: Expression of the above molecules involved in reverse cholesterol/lipid transport was assessed in rats 8 weeks after 5/6 nephrectomy (CRF) or sham operation.
RESULTS: CRF caused heavy accumulation of neutral lipids, upregulation of SR-AI, LOX-1, LXRalpha/beta, ABCA1 and ABCG1 in the aorta, reduction in LCAT in the plasma and no significant change in either SR-BI or beta-chain ATP synthase in the liver.
CONCLUSIONS: Lipid accumulation despite upregulation of the efflux (LXR, ABCA1, ABCG1) system in the aorta in CRF is largely due to upregulation of influx (SR-AI and LOX-1) pathway and LCAT deficiency. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19321994      PMCID: PMC2813810          DOI: 10.1159/000210020

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  37 in total

Review 1.  Liver X receptor signaling pathways in cardiovascular disease.

Authors:  Peter Tontonoz; David J Mangelsdorf
Journal:  Mol Endocrinol       Date:  2003-04-10

Review 2.  The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor.

Authors:  M S Brown; J L Goldstein
Journal:  Cell       Date:  1997-05-02       Impact factor: 41.582

3.  Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosis.

Authors:  Nosratola D Vaziri; Tadashi Sato; Kaihui Liang
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

4.  Downregulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH.

Authors:  N D Vaziri; Z Ni; X Q Wang; F Oveisi; X J Zhou
Journal:  Am J Physiol       Date:  1998-04

Review 5.  Molecular physiology of reverse cholesterol transport.

Authors:  C J Fielding; P E Fielding
Journal:  J Lipid Res       Date:  1995-02       Impact factor: 5.922

6.  Identification of scavenger receptor SR-BI as a high density lipoprotein receptor.

Authors:  S Acton; A Rigotti; K T Landschulz; S Xu; H H Hobbs; M Krieger
Journal:  Science       Date:  1996-01-26       Impact factor: 47.728

7.  Lead-induced hypertension: interplay of nitric oxide and reactive oxygen species.

Authors:  H C Gonick; Y Ding; S C Bondy; Z Ni; N D Vaziri
Journal:  Hypertension       Date:  1997-12       Impact factor: 10.190

Review 8.  Oxidative stress in uremia: nature, mechanisms, and potential consequences.

Authors:  Nosratola D Vaziri
Journal:  Semin Nephrol       Date:  2004-09       Impact factor: 5.299

Review 9.  The plasma lecithins:cholesterol acyltransferase reaction.

Authors:  J A Glomset
Journal:  J Lipid Res       Date:  1968-03       Impact factor: 5.922

10.  Impaired metabolism of high density lipoprotein in uremic patients.

Authors:  T Shoji; Y Nishizawa; H Nishitani; M Yamakawa; H Morii
Journal:  Kidney Int       Date:  1992-06       Impact factor: 10.612

View more
  16 in total

1.  Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease.

Authors:  Nosratola D Vaziri; Kaveh Navab; Pavan Gollapudi; Hamid Moradi; Madeleine V Pahl; Cyril H Barton; Alan M Fogelman; Mohamad Navab
Journal:  J Natl Med Assoc       Date:  2011-06       Impact factor: 1.798

Review 2.  Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease.

Authors:  Nosratola D Vaziri
Journal:  Clin Exp Nephrol       Date:  2013-08-24       Impact factor: 2.801

Review 3.  Statins in the management of dyslipidemia associated with chronic kidney disease.

Authors:  Murray Epstein; Nosratola D Vaziri
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

4.  Dysregulation of hepatic fatty acid metabolism in chronic kidney disease.

Authors:  Kyubok Jin; Keith Norris; Nosratola D Vaziri
Journal:  Nephrol Dial Transplant       Date:  2012-10-08       Impact factor: 5.992

5.  Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I production.

Authors:  Hamid Moradi; Hamid M Said; Nosratola D Vaziri
Journal:  Transl Res       Date:  2012-12-03       Impact factor: 7.012

Review 6.  Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.

Authors:  Nosratola D Vaziri; Keith C Norris
Journal:  Blood Purif       Date:  2013-01-22       Impact factor: 2.614

7.  HDL Cholesterol Efflux Does Not Predict Cardiovascular Risk in Hemodialysis Patients.

Authors:  Chantal Kopecky; Sanam Ebtehaj; Bernd Genser; Christiane Drechsler; Vera Krane; Marlies Antlanger; Johannes J Kovarik; Christopher C Kaltenecker; Mojtaba Parvizi; Christoph Wanner; Thomas Weichhart; Marcus D Säemann; Uwe J F Tietge
Journal:  J Am Soc Nephrol       Date:  2016-09-09       Impact factor: 10.121

Review 8.  An update on the lipid nephrotoxicity hypothesis.

Authors:  Xiong Z Ruan; Zac Varghese; John F Moorhead
Journal:  Nat Rev Nephrol       Date:  2009-10-27       Impact factor: 28.314

9.  In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide.

Authors:  Nosratola D Vaziri; Hamid Moradi; Madeleine V Pahl; Alan M Fogelman; Mohamad Navab
Journal:  Kidney Int       Date:  2009-05-27       Impact factor: 10.612

Review 10.  HDL abnormalities in nephrotic syndrome and chronic kidney disease.

Authors:  Nosratola D Vaziri
Journal:  Nat Rev Nephrol       Date:  2015-11-16       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.